Short answer
Mineralys Therapeutics, Inc. (MLYS) filed its fiscal 2025 10-K annual report with the SEC on Mar 12, 2026.
- Top risk flagged: Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue
FY2025 key financial metrics · XBRL
- Net income
- −$155M
- +13.0% YoY
- EPS (diluted)
- −$2.29
- +37.4% YoY
- ROE
- -23.9%
- +69.1 pp YoY
- Operating cash flow
- −$142M
- +14.4% YoY
Source: XBRL data from the Mineralys Therapeutics, Inc. (MLYS) FY2025 10-K on SEC EDGAR. USD.
Mineralys Therapeutics, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Business section lacks substantive description of core operations or products
- Reliance on 2026 Proxy Statement for key corporate governance and executive compensation details
- No disclosure of new products, services, strategic shifts, or geographic expansions this year
- References Ernst & Young LLP as principal independent auditor for 2026 financial statements
- Unusual focus on compliance codes and proxy statement incorporation, minimal direct business narrative
Management Discussion & Analysis
- No revenue; net loss $154.7M in 2025 vs $177.8M in 2024, improvement of $23.1M
- R&D expenses $132.0M in 2025 vs $168.6M in 2024, a 21.7% decrease; G&A expenses $38.6M vs $23.8M, a 62.0% increase
- No segments disclosed; entire focus on lorundrostat development and clinical trials
- Cash, cash equivalents, and investments $656.6M at year-end 2025; raised $269.6M in Sept 2025, $188.7M in Mar 2025, and $139.6M via ATM offering through Mar 2026
- Management expects cash to fund operations for at least 12 months; key risk is timing and success of regulatory approval and clinical trial outcomes
Risk Factors
- Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue
- Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations
- Supply chain risk: Dependency on third-party CMOs for cGMP-compliant manufacturing scale-up of lorundrostat, potential delays and cost increases
- Competitive risk: Market acceptance risk due to potential competing products and alternative therapies affecting lorundrostat launch prospects
- Financial risk: Accumulated deficit $457.2M with net losses $154.7M in 2025; need substantial capital raises risking dilution or restrictive debt covenants
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.